Business Context and Reporting Period
Company: Glucotrack, Inc. (GCTK)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Glucotrack is a medical device company developing the Glucotrack CBGM, an implantable continuous blood glucose monitor for Type 1 and Type 2 diabetes patients. The company abandoned its first-generation non-invasive product in 2023 to focus exclusively on the implantable CBGM. As of the reporting date, the company has no commercial revenue and is in the pre-clinical and early clinical development phase.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(19,388) | $(22,597) |
| Operating Expenses | $16,090 | $14,547 |
| Cash and Cash Equivalents (Year-End) | $7,383 | $5,617 |
| Accumulated Deficit | $(151,838) | $(132,450) |
| Derivative Liabilities | $1 | $17,421 |
| Promissory Notes (Current) | $3,182 | $0 |
Note: The company reported no revenue for either period. The reduction in net loss in 2025 was primarily driven by a decrease in "Other (income) expense" due to the settlement of derivative liabilities and reduced losses on equity issuance, offset by a $3.3 million increase in the change in fair value of derivative liabilities.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $3.2 million (14%) from 2024 to 2025. This improvement was not operational but resulted from non-cash accounting adjustments related to the settlement of derivative liabilities and equity issuances.
- Operating Expenses: Total operating expenses increased by $1.5 million (10%). Research and Development (R&D) expenses rose by $314,000 due to product design and pre-clinical studies. General and Administrative (G&A) expenses increased by $1.2 million, driven by higher professional fees and personnel costs.
- Liquidity Position: Cash and cash equivalents increased by $1.7 million to $7.4 million, funded by $17.0 million in net proceeds from financing activities (including ATM sales, registered direct offerings, and private placements).
- Capital Structure: The company executed two reverse stock splits in 2025 (1-for-20 in February and 1-for-60 in June) to regain compliance with Nasdaq listing requirements. Significant warrant exchanges and repurchases occurred, reducing derivative liabilities from $17.4 million to $1.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Clinical Progress
- Clinical Trials: The company completed a First-in-Human (FIH) acute study in 2025 with positive safety and performance results. A long-term feasibility study in Australia was closed due to protocol impracticalities. The company is preparing to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026, with a planned U.S. clinical trial launch in H2 2026.
- Technology: The company has demonstrated sensor longevity of up to 3 years in in-vitro and in-silico tests. It holds ISO 13485 certification.
Risks and Contingencies
- Going Concern: The independent auditor has issued an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern. Management states that current cash ($7.4 million) is insufficient to fund operations for the next 12 months without additional financing.
- Capital Needs: The company requires significant additional capital to fund clinical trials and commercialization. Failure to secure financing could force the curtailment of operations.
- Nasdaq Compliance: The company faced delisting risks due to bid price and stockholders' equity requirements but regained compliance through reverse stock splits and capital raises. A proposed new Nasdaq rule requiring a $5 million market value of listed securities poses a future delisting risk.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including insufficient accounting personnel and lack of segregation of duties. Remediation efforts are ongoing.
Unusual Items
- Derivative Liability Fluctuations: A significant portion of the 2025 net loss was driven by a $3.3 million expense related to the change in fair value of derivative liabilities, partially offset by gains from the settlement of these liabilities.
- Executive Departure: Peter C. Wulff, the Chief Financial Officer, resigned effective March 31, 2026, shortly after the fiscal year-end.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $7.4 million cash balance against the projected burn rate for the upcoming U.S. clinical trials and the timeline for the next capital raise.
- Going Concern Status: Review the specific terms of the auditor's "substantial doubt" opinion and management's detailed plan to secure financing.
- Regulatory Pathway: Confirm the status of the FDA IDE submission expected in Q2 2026 and the specific requirements for the De Novo 510(k) pathway versus PMA.
- Internal Controls: Assess the progress of remediation for the identified material weaknesses in financial reporting and IT controls.
- Dilution Risk: Analyze the impact of outstanding warrants (including pre-funded warrants exercised post-year-end) and the potential for further dilution from future equity financings.
- Nasdaq Listing: Monitor the company's compliance with Nasdaq listing rules, particularly regarding the proposed $5 million market value requirement.